The data underlying the results presented in the study is available in supporting information file.

Introduction {#sec005}
============

Total joint replacement is the last resort treatment for degenerative joint disease. A feared complication is prosthetic joint infection (PJI) with an incidence of 1--2% after primary hip arthroplasty and 1--4% after primary knee arthroplasty \[[@pone.0233086.ref001]\]. PJI is difficult to treat as the bacteria form a biofilm on the prosthetic material. This hinders the host immune system, but more important, the bacteria in a biofilm are mostly in a dormant state and therefore not susceptible to most antibiotics \[[@pone.0233086.ref002]\]. Alpha or beta radiation could potentially damage or destroy these dormant cells because, in contrary to antibiotics, the damaging effects are independent of the cell\'s metabolic state. However, due to the limited tissue penetration of both alpha and beta radiation it is crucial to get the radionuclide in close vicinity to the cells. Radioimmunotherapy (RIT) relies on the antigen-binding characteristics of the monoclonal antibodies (mAbs) to deliver cytotoxic radiation to target cells and is successfully used in oncology \[[@pone.0233086.ref003]\]. As microbes express antigens that are unique and different from host antigens, they can be targeted with high specificity and low cross-reactivity. In the past we demonstrated that fungal cells could be eliminated in vitro and in vivo with the radiolabeled microorganism-specific mAbs \[[@pone.0233086.ref004]\], and later expanded this approach to other fungal and bacterial pathogens such as *Streptococcus pneumoniae* and *Bacillus anthracis* as well as HIV \[reviewed in [@pone.0233086.ref005]\]. This implies that bacterial infections of the prosthetic joints can also, in principle, be treated with RIT. The hypothesis underlying the current study is that radioisotopes Lutetium-177 (^177^Lu; a beta-emitter), and Actinium-225 (^225^Ac; an alpha-emitter) or Bismuth-213 (^213^Bi; an alpha-emitter) are able to eradicate *Staphylococcus aureus* using RIT with mAbs directed towards the bacterial cell wall and the biofilm. *S*. *aureus* is the most common pathogen involved in PJI \[[@pone.0233086.ref006]\] and therefore this proof-of-principle data is required for further development of RIT for non-invasive treatment of PJIs.

Materials and methods {#sec006}
=====================

Growth of bacterial cultures {#sec007}
----------------------------

A methicillin-resistant AH4802-LAC strain of *Staphylococcus aureus* \[[@pone.0233086.ref007]\] was a kind gift from Dr. A.R. Horswill, Professor of Immunology & Microbiology at the University of Colorado, CO, USA. This strain is a known biofilm former on diverse surfaces. For both planktonic growth and biofilm formation, the bacteria were transferred from the frozen stock onto blood agar plates (Tryptic Soy Agar (TSA) with 5% sheep blood) and aerobically cultured overnight at 37°C. After incubation, 3--4 single colonies were emulsified in tryptic soy broth (TSB) and incubated overnight at 37°C with agitation (150--200 RPM).

For planktonic growth, the cultures were vortexed for 30 seconds after incubation and thereafter diluted 1:100 in TSB. Bacteria were grown for 3--4 hours until logarithmic phase was reached. The cultures were vortexed for 1 min and measured on a microplate reader (Spectra MAX 250, Molecular Devices, USA) at 600 nm. The cells were washed twice and re-suspended in sterile phosphate buffered saline (PBS). The diluted bacteria were vortexed for 10 seconds after which 100 μl of this suspension was added to the appropriate number of wells of a sterile flat-bottomed 96-well polystyrene tissue culture-treated microtiter plate with a lid (Fisher Scientific).

Biofilm formation was standardized and based on the recommendations described by Stepanović et al. \[[@pone.0233086.ref008]\]. After initial incubation, the culture was vortexed for 30 seconds and thereafter diluted 1:100 in TSB supplemented with 1% glucose to reach approximately 10^6^ colony forming units (CFU)/ml, measured at 600 nm. The diluted bacteria were vortexed for 10 seconds after which 100 μl of this suspension was added to the appropriate number of wells of the same type of 96-well plate used for planktonic bacteria. The outer wells were filled with 200 μl of sterile PBS to counter dehydration of the biofilms. The plate was cultured aerobically and under static conditions for 24 hours at 37°C. After incubation the medium was carefully removed by pipetting and the biofilms were washed twice with sterile PBS to remove non-adherent bacteria. Finally 50 μl of sterile PBS was added to each well containing biofilms. All assays were carried out in duplicate.

Antibodies and radiolabeling {#sec008}
----------------------------

To deliver the radionuclides to the bacteria and biofilms, human mAb anti-β GlcNAc-IgG1 antibody 4497 that targets wall teichoic acids (WTAs) was used \[[@pone.0233086.ref009]\]. WTAs are cell surface-exposed glycopolymers on *S*. *aureus* cells that are also found within the extracellular matrix of the biofilm \[[@pone.0233086.ref010]\]. Thus, this antibody targets both bacteria and biofilm. Human mAb Palivizumab (IgG1) against respiratory syncytial virus (RSV) was acquired from MedImmune and was used as an isotype-matching negative control for non-specific killing of bacteria. Unlabeled 4497 and Palivizumab mAbs were also used as controls. MAbs 4497 and Palivizumab were conjugated to bifunctional chelating agents CHXA" or DOTA (Macrocyclics, USA) using a 10- or 20-fold molar excess over mAb as described earlier \[[@pone.0233086.ref011]\]. Conjugated antibody was radiolabeled with three different radioisotopes, ^213^Bismuth, ^177^Lutetium and ^225^Actinium. Radiolabeling of the antibody-CHXA" conjugate with ^177^Lu and ^213^Bi was performed to achieve a specific activity of 185 kBq/μg of the antibody whereas for the radiolabeling of antibody-DOTA conjugate with ^225^Ac a specific activity of 37 kBq/μg was desired.

^213^Bi was eluted from the generator with 200 μL of freshly prepared 2% (v/v) HI solution in deionized H~2~O followed by 100 μL of deionized H~2~O. To facilitate radiolabeling, the pH was adjusted to 7 using 80 μL of 5M ammonium acetate solution and the radioactivity was measured on a dose calibrator. An appropriate amount of Ab-CHXA" was then added to achieve the desired specific activity and the reaction was heated at 37°C for 5 minutes with shaking. The reaction was then quenched by the addition of 3 μL of 0.05 M EDTA solution to bind any free ^213^Bi. To purify the mixture the solution was then added to an Amicon Ultra 0.5 mL centrifugal filter (30K MW cut off, Fisher Scientific) and spun for 3 minutes at 14 000 g, followed by 300 uL of PBS was and spun again. The purified solution was collected and the percentage of radiolabeling (radiolabeling yield) was measured by instant thin layer chromatography (iTLC) by developing 10 cm silica gel strips (Agilent Technologies, CA, USA) in 0.15 M ammonium acetate buffer. In this system the radiolabeled antibodies stay at the point of application while free ^213^Bi, in the form of EDTA complexes, moves with the solvent front. The strips were cut in half and each half is counted on a 2470 Wizard2 Gamma counter (Perkin Elmer, MA, USA) that was calibrated for the ^213^Bi emission spectrum and only emissions in this range were considered in the CPM. The percentage of radiolabeling is calculated by dividing the counts per minute (CPM) at the bottom of the strip (labeled antibody) by the sum of the CPM at the bottom and the top of the strip (total amount of radioactivity) and multiplying the result by 100. Typical yields were greater than 95%.

^177^Lu chloride was diluted with 0.15 M ammonium acetate buffer and added to a microcentrifuge tube (MCT) containing the mAb-CHXA" conjugate in the 0.15 M ammonium acetate buffer in a reaction volume of \~30 μL. The reaction mixture was incubated for 60 min at 37°C. The reaction was then quenched by the addition of 3 μL of 0.05 M EDTA solution to bind any free ^177^Lu. Labelling efficiency was then measured in the same manner described above using iTLC. Typical yields were greater than 95% and required no further purification.

^225^Ac labelling was performed similarly to ^177^Lu, however to accommodate the larger size of ^225^Ac an antibody-DOTA conjugate had to be used, Three μL of 0.05M Diethylenetriamine pentaacetate (DTPA) solution was used to quench the reaction. iTLC were read 24h after running to allow for secular equilibrium to be reached. Yields were typically greater than 98% and required no further purification.

Determination of the bactericidal effect of RIT on *S*. *aureus* {#sec009}
----------------------------------------------------------------

*S*. *aureus* AH4802 planktonic cells and biofilms were treated with three different radionuclides at different doses for 1 hour at 37°C. The doses for ^177^Lu were 14.8, 7.4, 3.7 MBq and for ^225^Ac 7.4, 3.7 and 1.85 kBq on for both planktonic and biofilm. 370, 185, 111, 74, and 37 kBq of ^213^Bi was used on planktonic bacteria and 185, 111 and 37 kBq was used on biofilms. Alpha particles have higher (100 keV/μm) linear energy transfer when compared to beta particles (0.8 keV/μm) and can produce considerably more lethal double strand DNA breaks along their tracks. Therefore, ^177^Lu (half-life 6.7 days, 0.5 MeV), being a beta-emitter, needs higher activities to deliver a lethal absorbed dose when compared to alpha-radiation. During its decay, ^225^Ac (half-life 10 days, 5.9 MeV) emits four α-particles versus one α-particles emitted by ^213^Bi (half-life 46 min, 5.9 MeV). Thus, ^225^Ac is lethal at lower activities when compared to ^213^Bi and therefore a lower radiation dose of ^225^Ac is used.

After incubation, the 96-wells plates were centrifuged for 7 min at 3,500 RPM, washed twice and the pellets were re-suspended in 100 μl sterile PBS. The biofilms were sonicated for 30 seconds to detach the cells. Viability and metabolic activity of the bacterial cells and biofilms were measured by CFU dilution and XTT reduction. For viability testing, 20 μl of each well was used to make a serial dilution, cultured overnight on blood agar plates and counted for colony forming units (CFU). Metabolic activity was measured by adding 50 μl of freshly mixed 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) solution (from XTT cell proliferation kit II, Sigma) to the remaining 80 μl of the bacterial solution in each well. The plates are covered in aluminum foil and incubated for 3 hours at 37°C under static conditions. The colorimetric change was read in an ELISA plate reader (Labsystem Multiskan, Franklin, MA) at 492 nm absorbance. Colorimetric change is the result of mitochondrial dehydrogenase activity that reduced XTT tetrazolium salt to XTT formazan. Thus, the more colorimetric change the more metabolic activity there is. Two wells with sterile PBS were used as blank control. Significant differences between treatment groups and their corresponding controls were calculated using one-way ANOVA with a post-hoc Tukey test.

Results {#sec010}
=======

Multiple experiments were done to assess the efficacy of RIT on planktonic *MRSA* and biofilms. First, planktonic bacteria were treated with 14,8, 7,4 and 3,7 MBq of beta-emitter ^177^Lu bound to the specific WTA-specific mAb 4497 and to the non-specific mAb Palivizumab. XTT results were compared to the unlabeled controls. ([Fig 1A and 1B](#pone.0233086.g001){ref-type="fig"}). No significant reduction of cells was seen between treatment groups and their controls (p = \>0,05). A significant difference in metabolic activity was seen between the specific and non-specific antibodies loaded with 7,4 MBq of ^177^Lu (p = 0.033). Second, planktonic bacteria were treated with 7,4, 3,7, and 1,85 kBq of alpha-emitter ^225^Ac bound to the same antibodies. No significant difference was seen in CFU count between the groups apart from the non-specific treatment group bound to 3.7 kBq of ^225^Ac compared to the control. (p = \>0,05) A significant increase in metabolic activity was seen in all treatment groups compared to both controls and corresponding radiation dose. (p = \> 0,05) ([Fig 1C and 1D](#pone.0233086.g001){ref-type="fig"}). WTA-specific mAb ^225^Ac-4497 showed an increase in metabolic activity when compared the labeled non-specific antibodies. Third, planktonic bacteria were treated with 370, 185, 111, 74 and 37 kBq of ^213^Bi. When treatment groups were compared to their controls, a significant reduction in survival was seen in the WTA-specific mAb 4497 group with 370, 185 and 111 kBq (p = 0,002, p = 0,008 resp. p = 0,032) when compared to the control. Also, a significant reduction was seen with the non-specific antibodies 370 and 185 kBq compared to the control (p = 0,003 resp. p = 0,036).

![Susceptibility of [planktonic](http://www.apple.com/) *S*. *aureus* (*MRSA*) to beta and "short and long-lived" alpha radiation measured by CFU/ml for survivability (A,C,E) and XTT reduction assay for the metabolic activity (B,D,F).\
Increasing doses of RIT with specific anti-WTA 4497 antibodies and non-specific antibodies Palivizumab labeled with ^177^Lu (A,B), ^225^Ac (C,D) and ^213^Bi (E,F). Treatment results were compared to unlabeled 4497 mAb,Palivizumab, and iodine controls. Each data point represents the average of two measurements.](pone.0233086.g001){#pone.0233086.g001}

After the planktonic experiments, biofilms were treated with RIT. The WTA-specific mAb 4497 groups with ^177^Lu, ^225^Ac and ^213^Bi showed no significant difference in CFU count compared to the control although there was no bacterial growth with 185 kBq ^213^Bi bound to WTA and Palivizumab antibodies ([Fig 2](#pone.0233086.g002){ref-type="fig"}). There was a significant difference in metabolic activity between ^177^Lu bound to the non-specific antibodies compared to the control (p = 0,026) and a significant difference, in favor of the specific antibody, between the WTA-specific mAb 4497 with a radiation dose of 7.4 MBq when compared to the same dose of the non-specific antibody (p = 0,011). In the non-specific antibody group of ^225^Ac with 1.85 kBq, a significant difference was seen in metabolic activity when compared to the control (p = 0,029). A significant difference in metabolic activity was seen in WTA-specific mAb 4497 loaded with 185 and 111 kBq of ^213^Bi when compared to the control (p = 0,014 resp. p = 0,045) Also, a significant difference in metabolic activity was seen in the non-specific antibody group loaded with 185 kBq of ^213^Bi compared to the control (p = 0,018). There was a significant difference in metabolic activity between the specific and non-specific antibodies loaded with 111 and 74 kBq of ^213^Bi (p = 0,037 resp. p = 0,026). There was no significant difference seen in metabolic activity between the specific and non-specific antibodies loaded with the highest dose of 185 kBq ^213^Bi because all the plates were sterile.

![Susceptibility of *S*. *aureus* (*MRSA*) biofilm to beta and "short and long-lived" alpha radiation measured by CFU/ml for survivability (A,C,E) and XTT reduction assay for the metabolic activity (B,D,F).\
Increasing doses of RIT with specific anti-WTA 4497 antibodies and non-specific antibodies Palivizumab labeled with ^177^Lu (A,B), ^225^Ac (C,D) and ^213^Bi (E,F). Treatment results were compared to unlabeled 4497 mAb,Palivizumab, and iodine controls. Each data point represents the average of two measurements.](pone.0233086.g002){#pone.0233086.g002}

Discussion {#sec011}
==========

The need for alternative treatment options for patients with implant infections like periprosthetic joint infections grows every year, not only due to increasing pathogen resistance to antibiotics, but also because biofilm formation obstructs the treatment of these infections with antibiotics. To the best of our knowledge, this is the first report of RIT treatment of MRSA in particular and of any multidrug resistant bacteria in general in both planktonic and biofilm state. ^213^Bi-labeled mAb WTA 4497 consistently killed both planktonic bacteria and biofilm as measured by both XTT and CFU assays. A significant decrease in both CFU count and metabolic activity was seen in planktonic bacteria when treated with 370, 185 and 111 kBq 213Bi-WTA-specific mAb 4497 versus 370 and 185 kBq of 213Bi-Palivizumab ([Fig 1E and 1F](#pone.0233086.g001){ref-type="fig"}). Although statistically not significant, biofilms treated with specific and non-specific antibodies labeled with 185 kBq of ^213^Bi showed no residual bacterial growth with the effect being similar to that of Iodine solution, being used as a positive control. (Figs [1](#pone.0233086.g001){ref-type="fig"} and [2](#pone.0233086.g002){ref-type="fig"}). Also, a significant decrease in metabolic activity was seen in biofilms treated with specific antibodies labeled with 185 and 111 kBq of ^213^Bi and non-specific antibodies labeled with 185 kBq ([Fig 2E and 2F](#pone.0233086.g002){ref-type="fig"}). The decrease in survival and metabolic activity in both planktonic bacteria and biofilms treated with 370 and 185 kBq ^213^Bi groups was probably due to high levels of radioactivity in a small volume causing non-specific killing. Nonetheless, ^213^Bi showed a dose dependent killing of planktonic bacteria and biofilms. Interestingly, specific antibodies labeled with 111 kBq showed significantly more killing of planktonic bacteria and biofilms in both CFU count and XTT when compared to non-specific antibodies loaded with the same amount of radiation, suggesting that specific targeting is more effective. This could mean that mAb ^213^Bi-4497 specifically targets individual cells. In this regard, the non-specific killing by both radiolabeled bacterium-specific and non-specific antibodies results from one or combination of two events: 1) in vitro there is always some non-specific killing of cells by highly destructive alpha and beta particles emitted by the radionuclides in a small volume of an assay; 2) WTA-specific 4497 and RSV mAbs are human monoclonal antibodies which, on average, have much higher isoelectric points (IP) than murine antibodies. Antibodies with higher IPs have a tendency to non-specifically bind to the cells, therefore, both radiolabeled 4497 and RSV mAbs demonstrated some non-specific therapeutic effect towards bacterial cells. However, the killing effect of radiolabeled with ^213^Bi 4497 mAb was higher than that of radiolabeled RSV mAb under examined conditions, indicating that killing of MRSA by ^213^Bi-4497 mAb was WTA-specific". This also suggests that α-particles are able to effectively penetrate the architecture of the biofilms to deliver bactericidal radiation to the cells. Encouragingly, the dose required for killing *S*. *aureus* in a biofilm was of the same order of magnitude as the dose required to kill planktonic cells. ^177^Lu-4497 mAb did not have an effect on planktonic bacteria and the biofilm, whereas ^225^Ac seemed to even increase metabolic activity in planktonic and biofilm formation. This was probably due to the biofilm matrix release and thus bacterial release, caused by alpha-radiation, which interferes with XTT and gives an increase in CFU when compared to the unlabeled controls. It is possible, that due to the long physical half-lives of ^225^Ac (10 days) and ^177^Lu (6.7 days) it might take longer than the 1 hour incubation to reveal the full bactericidal potential of these long lived radionuclides but longer incubation time might also improve the damaging effect of ^213^Bi.

Previously we have performed extensive evaluation of RIT toxicity in mouse models of fungal and bacterial infections using the antibodies labeled with the same ^213^Bi radionuclide utilized in this work. No systemic toxicity was noted in mice infected with *Streptococcus pnemoniae* and treated with ^213^Bi-labeled antibody to bacterial polysaccharide \[[@pone.0233086.ref012]\]. The toxicity evaluation of RIT-treated mice infected intratracheally with *C*. *neoformans* showed the absence of acute hematologic and long-term pulmonary toxicity \[[@pone.0233086.ref013]\]. RIT was much better tolerated by the treated mice than Amphoterecin B which is a current standard of care for invasive fungal infections \[[@pone.0233086.ref014]\]. In addition, RIT did not adversely affect bystander mammalian cells such as CHO cells and macrophages, with the latter being able to carry out their functions such as nitric oxide production after RIT exposure \[[@pone.0233086.ref015]\]. As all these observations have been made for systemic administration of the radiolabeled antibodies, the anticipated local application of RIT into the infected joint should be even safer in this regard.

In conclusion, our results demonstrate the ability of specific antibodies loaded with an alpha-emitter ^213^Bi to selectively kill *S aureus* cells in vitro in both planktonic and biofilm state. RIT could therefore be a potentially alternative treatment modality against planktonic and biofilm-related microbial infections and can be used with and without conventional therapies such as antibiotics. However, this in vitro observed bactericidal effect of RIT on *S*. *aureus* must be validated in vivo and the work in the animal models of MRSA infection is currently on-going.
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4\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ> -- Response:

ORCID iD has been linked to the manuscript.

5\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data. -- Response: We are now showing this data in the modified figures.
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PONE-D-19-33702R1

Radioimmunotherapy of Methicillin-resistant Staphylococcus aureus in planktonic state and biofilms

PLOS ONE

Dear Dr Dadachova

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, reviewer recommends more experimental work to be done.

We would appreciate receiving your revised manuscript by May 30 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Amal Al-Bakri

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript expands on the growing repertoire of immunotherapy applications, outside of cancer. The authors have provided a proof-of-concept study investigating radioimmunotherapy for the treatment of Methicillin-resistant staphylococcus aureus. As such, rigorous experimentation as been performed and the data provided is sufficient. This research indeed contributes to a gap in the field of therapeutic options for prosthetic joint infection (PJI) and offers a novel approach. No additional revision is required, as authors have adequately addressed the comments of previous reviewer. Furthermore, this manuscript adheres to PLOS ONE criteria.

Reviewer \#2: The authors have addressed the issues raised in the previous review. However, there is little innovation here. It is not clear that there is a specific antibody effect and whatever was observed would be expected. An in vivo study would generate more interest.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Dr. Krupa Naran

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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20 Apr 2020

Reviewer \#2:

The authors have addressed the issues raised in the previous review. However, there is little innovation here. It is not clear that there is a specific antibody effect and whatever was observed would be expected. An in vivo study would generate more interest. -- Response: We would like to thank the Reviewer for acknowledging that we have addressed the issues in the previous review.

We respectfully disagree about the lack of the innovation. In the revised manuscript we have expanded the sentence in the Discussion stating that: "To the best of our knowledge, this is the first report of RIT treatment of MRSA in particular and of any multidrug resistant bacteria in general in both planktonic and biofilm state".

We have also added the explanation about some non-specfic killing to the Discussion: "In this regard, the non-specific killing by both radiolabeled bacterium-specific and non-specific

antibodies results from one or combination of two events: 1) in vitro there is always some non-specific killing of cells by highly destructive alpha and beta particles emitted by the radionuclides in a small volume of an assay; 2) WTA-specific 4497 and RSV mAbs are human monoclonal antibodies which, on average, have much higher isoelectric points (IP) than murine antibodies. Antibodies with higher IPs have a tendency to non-specifically bind to the cells, therefore, both radiolabeled 4497 and RSV mAbs demonstrated some non-specific therapeutic effect towards bacterial cells. However, the killing effect of radiolabeled with 213Bi 4497 mAb was higher than that of radiolabeled RSV mAb under examined conditions, indicating that killing of MRSA by 213Bi-4497 mAb was WTA-specific".

In regard to the animal experiments, they are out of scope of this proof of principle manuscript.

Currently on-going work in animal models on non-invasive nuclear imaging, therapy and safety evaluation will be reported in a follow-up manuscript. We have added a sentence to the conclusions that "the work in the animal models of MRSA infection is currently on-going".
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Dear Dr. Dadachova, 

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Amal Al-Bakri

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: While the reviewers did not provide in vivid data, I think the concept is novel enough to warrant publication in the hopes that in vivid data will be forthcoming

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: Yes: Malik E Juweid
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Radioimmunotherapy of Methicillin-resistant *Staphylococcus aureus* in planktonic state and biofilms

Dear Dr. Dadachova:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Amal Al-Bakri

Academic Editor

PLOS ONE
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